Retrieve available abstracts of 15 articles: HTML format
Single Articles
August 2025
CHEN C, Gao Y, Lu R, Wu Y, et al TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression.
Cancer Res. 2025 Aug 4. doi: 10.1158/0008-5472.CAN-24-3439. PubMedAbstract available
March 2025
YU Y, Gao X, Zhao H, Sun J, et al A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target
to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.
Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-3217. PubMedAbstract available
December 2024
PRABAGAR MG, McQueney M, Bommireddy V, Siegel R, et al THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY
INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER.
Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-1022. PubMedAbstract available
September 2024
CUI C, Zhang H, Yang C, Yin M, et al Inhibition of JNK Signaling Overcomes Cancer-Associated Fibroblast-Mediated
Immunosuppression and Enhances the Efficacy of Immunotherapy in Bladder Cancer.
Cancer Res. 2024 Sep 18. doi: 10.1158/0008-5472.CAN-24-0940. PubMedAbstract available
August 2024
KELLER PJ, Adams EJ, Wu R, Cote A, et al Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for
Targeting of ARID1A Mutant Cancers.
Cancer Res. 2024;84:2501-2517. PubMedAbstract available
July 2024
ZENG Y, Luo Y, Zhao K, Liu S, et al m6A-Mediated Induction of 7-Dehydrocholesterol Reductase Stimulates Cholesterol
Synthesis and cAMP Signaling to Promote Bladder Cancer Metastasis.
Cancer Res. 2024 Jul 24. doi: 10.1158/0008-5472.CAN-23-3703. PubMedAbstract available
YANG Y, Suhasini AN, Jiang Z, Liu N, et al A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic
Variants.
Cancer Res. 2024;84:2169-2180. PubMedAbstract available
May 2024
JONES RT, Scholtes M, Goodspeed A, Akbarzadeh M, et al NPEPPS Is a Druggable Driver of Platinum Resistance.
Cancer Res. 2024;84:1699-1718. PubMedAbstract available
March 2024
HOSNI S, Kilian V, Klumper N, Gabbia D, et al Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in
Urothelial Carcinoma.
Cancer Res. 2024;84:725-740. PubMedAbstract available
November 2023
ZHAO Y, Chen J, Zheng H, Luo Y, et al SUMOylation-driven mRNA circularization enhances translation and promotes
lymphatic metastasis of bladder cancer.
Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278. PubMedAbstract available
September 2023
OUYANG Y, Ou Z, Zhong W, Yang J, et al FGFR3 alterations in bladder cancer stimulate serine synthesis to induce
immune-inert macrophages that suppress T-cell recruitment and activation.
Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065. PubMedAbstract available
April 2023
OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al Correction: ARF Confers a Context-Dependent Response to Chemotherapy in
Muscle-Invasive Bladder Cancer.
Cancer Res. 2023;83:1159. PubMed
March 2023
ZHUANG J, Shen L, Li M, Sun J, et al Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes
bladder cancer stemness and chemoresistance.
Cancer Res. 2023 Mar 20:CAN-22-2213. doi: 10.1158/0008-5472.CAN-22-2213. PubMedAbstract available
ZHANG L, Li Y, Zhou L, Zhou H, et al The m6A reader YTHDF2 promotes bladder cancer progression by suppressing
RIG-I-mediated immune response.
Cancer Res. 2023 Mar 20:CAN-22-2485. doi: 10.1158/0008-5472.CAN-22-2485. PubMedAbstract available
XIE R, Cheng L, Huang M, Huang L, et al NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in
bladder cancer.
Cancer Res. 2023 Mar 20:CAN-22-2233. doi: 10.1158/0008-5472.CAN-22-2233. PubMedAbstract available